Demystifying MASLD Management: Practical Guidance

Clinical Takeaway

: The American Gastroenterological Association’s updated clinical care pathway clarifies MASLD screening and treatment recommendations.

An overview of Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (2026)

Background

This American Gastroenterological Association (AGA) multidisciplinary task force guideline addresses screening protocols for metabolic dysfunction–associated steatotic liver disease (MASLD) and offers important management recommendations for primary care clinicians and specialists.

Key Recommendations

Screening and Evaluation

All patients with type 2 diabetes or obesity as well as overweight patients with any metabolic risk factor should be screened for MASLD-related fibrosis using the fibrosis-4 (FIB-4) index.
The FIB-4 index also should be used when evaluating patients with i…